CytoSorbents Corporation (CTSO)

[raptorjockey]

BG, After reading your post, I realize there are some similarities between the process and problems with planning reimbursements as they might apply with the Car-T evolution, ie, what will be covered, what will not and how that will change as the therapy matures. Of course, the simplest solution for us would be a blanket approval of our filter for elevated immunological response similar to the CE approval. However, we know the FDA is not so lenient when it comes to approving new therapies or modalities supporting those therapies. I would really like to see an in depth discussion, that addresses the questions regarding approvals, reimbursement, assignment of treatment codes, and the expectation of Cytosorb. No doubt Cytosorb has a plan in place and although some might say it would be premature to discuss these concerns, I don't think it's too early to address this with the share holders.